⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28159060 | 1.00 | — | — | |
| SCHEMBL21486205 | 1.00 | — | — | |
| SCHEMBL241042 | 1.00 | — | — | |
| SCHEMBL11464778 | 0.94 | — | — | |
| SCHEMBL9376112 | 0.94 | — | — | |
| SCHEMBL1908437 | 0.92 | — | — | |
| SCHEMBL16226877 | 0.92 | SCN2A (0.31) | — | |
| 1-Pentanol SCHEMBL27979326 | 0.88 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL23192858 | 0.86 | — | — | |
| SCHEMBL11923510 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135059-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY | 2025-05-01 | — | — | US | disclosed |
| US-10806683-B2 | Encapsulated perfume compositions | GIVAUDAN SA (CH) | 2020-10-20 | — | — | US | disclosed |
| US-10722857-B2 | Encapsulated perfume compositions | GIVAUDAN S.A. (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10537868-B2 | Microcapsules | GIVAUDAN S.A. (CH) | 2020-01-21 | — | — | US | disclosed |
| US-20180185808-A1 | MICROCAPSULES | GIVAUDAN SA (CH) | 2018-07-05 | — | — | US | disclosed |
| US-20180177689-A1 | IMPROVEMENTS IN OR RELATING TO ENCAPSULATED PERFUME COMPOSITIONS | GIVAUDAN S.A. (CH) | 2018-06-28 | — | — | US | disclosed |
| US-20180169603-A1 | IMPROVEMENTS IN OR RELATING TO ENCAPSULATED PERFUME COMPOSITIONS | GIVAUDAN S.A. (CH) | 2018-06-21 | — | — | US | disclosed |
| US-8987377-B2 | Poly(amide) polymers for the delivery of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20130253135-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-09-26 | — | — | US | disclosed |
| EP-2640400-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | Merck Sharp & Dohme Corp. (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2491032-A1 | AKT INHIBITORS | Eli Lilly and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012068187-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011050016-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |